Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 7, 2022 | Post-IPO Debt | $75M | 1 |
![]() |
— | Detail |
Jun 7, 2022 | Post-IPO Equity | $5M | 1 |
![]() |
— | Detail |
Oct 26, 2017 | Post-IPO Equity | $19.50M | — | — | — | Detail |
Jan 4, 2017 | Post-IPO Debt | $25M | 1 |
|
— | Detail |
Apr 29, 2016 | Post-IPO Equity | $2.99M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Post-IPO Debt |
|
Yes | Post-IPO Debt |
![]() |
— | Debt Financing |
![]() |
— | Series A |
![]() |
— | Seed |